| dbo:abstract
|
- Cambridge Antibody Technology (officially Cambridge Antibody Technology Group Plc, informally CAT) was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using Phage Display and Ribosome Display technology. Phage Display Technology was used by CAT to create adalimumab, the first fully human antibody blockbuster drug. Humira, the brand name of adalimumab, is an anti-TNF antibody discovered by CAT as D2E7, then developed in the clinic and marketed by Abbvie, formerly Abbott Laboratories. CAT was also behind belimumab, the anti-BlyS antibody drug marketed as Benlysta and the first new approved drug for systemic lupus in more than 50 years. In 2018, the Nobel Prize organisation awarded one quarter of the Nobel Prize in Chemistry to a founding member of CAT, Sir Greg Winter FRS "for the phage display of peptides and antibodies.". Founded in 1989, CAT was acquired by AstraZeneca for £702m in 2006. AstraZeneca subsequently acquired MedImmune LLC, which it combined with CAT to form a global biologics R&D division called MedImmune. CAT was often described as the 'jewel in the crown' of the British biotechnology industry and during the latter years of its existence was the subject of frequent acquisition speculation. (en)
|
| dbo:assets
| |
| dbo:equity
| |
| dbo:fate
|
- Acquired byAstraZenecain 2006; combined withMedImmunein 2007 (en)
|
| dbo:foundedBy
| |
| dbo:foundingYear
| |
| dbo:keyPerson
| |
| dbo:location
| |
| dbo:netIncome
| |
| dbo:numberOfEmployees
|
- 300 (xsd:nonNegativeInteger)
|
| dbo:operatingIncome
| |
| dbo:owner
| |
| dbo:owningCompany
| |
| dbo:product
| |
| dbo:revenue
| |
| dbo:service
| |
| dbo:successor
| |
| dbo:thumbnail
| |
| dbo:type
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 91790 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:areaServed
| |
| dbp:assets
| |
| dbp:equity
| |
| dbp:fate
|
- Acquired by AstraZeneca in 2006; combined with MedImmune in 2007 (en)
|
| dbp:footnotes
|
- *Financials for six-month period prior to acquisition by AstraZeneca were distorted by the settlement for royalties payable on Adalimumab sales (en)
|
| dbp:foundation
| |
| dbp:founder
|
- David Chiswell, Sir Greg Winter, John McCafferty, Medical Research Council (en)
|
| dbp:industry
| |
| dbp:keyPeople
| |
| dbp:location
|
- Granta Park, Cambridgeshire, England, United Kingdom (en)
|
| dbp:logo
|
- Black with strap v2.png (en)
|
| dbp:logoSize
| |
| dbp:name
|
- Cambridge Antibody Technology Group Plc (en)
|
| dbp:netIncome
| |
| dbp:numEmployees
| |
| dbp:operatingIncome
| |
| dbp:owner
| |
| dbp:products
|
- Adalimumab, discovery of; belimumab discovery of (en)
|
| dbp:revenue
| |
| dbp:services
|
- Therapeutic monoclonal antibody discovery and development (en)
|
| dbp:successor
| |
| dbp:tradedAs
| |
| dbp:type
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Cambridge Antibody Technology (officially Cambridge Antibody Technology Group Plc, informally CAT) was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using Phage Display and Ribosome Display technology. (en)
|
| rdfs:label
|
- Cambridge Antibody Technology (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| foaf:name
|
- Cambridge Antibody Technology Group Plc (en)
|
| is dbo:knownFor
of | |
| is dbo:wikiPageDisambiguates
of | |
| is dbo:wikiPageWikiLink
of | |
| is dbp:knownFor
of | |
| is foaf:primaryTopic
of | |
